Benefit of Adding Panitumumab to FOLFOX4 in Patients with KRAS/NRAS Wild-Type (WT) Metastatic Colorectal Cancer (mCRC): A Number-Needed-To-Treat (NNT) Analysis

Jean‐Yves Douillard, R. Sidhu, S. Sienna et al.|Value in Health|2013

Cited by 1